| Indication | Obesity |
| Drug | HRS-7535 |
| Mechanism of Action | GLP-1 receptor agonist |
| Company | Hengrui Pharma |
| Trial Phase | Phase 3 |
| Trial Acronym | HARBOR-1 |
| NCT ID | NCT06904105 |
| Category | Regulatory Milestone |
| Sub Category | Regulatory Submission Filed |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Trial Name (Obesity) | HARBOR-1 |
| Trial Name (Type 2 Diabetes) | OUTSTAND-2 |
| Primary Endpoint (HARBOR-1) | Mean weight loss from baseline |
| Weight Loss (HARBOR-1, 180mg) | 9.8% at week 44 |
| Weight Loss (HARBOR-1, Placebo) | 2.4% reduction at week 44 |
| Comparator (OUTSTAND-2) | Dapagliflozin |
| HbA1c Reduction (OUTSTAND-2, 90mg HRS-7535) | 1.68% |
| Most Common Adverse Events | Nausea, Vomiting, Diarrhea |
| Nausea Rate (HRS-7535) | ~70% |
| Regulatory Submission Region | China |
Hengrui and Kailera's Oral GLP-1 Achieves Phase 3 Endpoints in China
Hengrui Pharma and Kailera Therapeutics announced positive late-stage results for their investigational oral GLP-1 receptor agonist, HRS-7535/KAI-7535, in China. The Phase 3 HARBOR-1 trial for obesity or overweight adults demonstrated mean weight loss of 8% and 9.8% from baseline at week 44 for 120 mg and 180 mg doses, respectively, significantly outperforming the 2.4% reduction in the placebo arm. Concurrently, the Phase 3 OUTSTAND-2 study for type 2 diabetes achieved non-inferiority to dapagliflozin, showing a 1.68% HbA1c reduction with the highest HRS-7535 dose. These results pave the way for regulatory submissions in China for both indications. However, high rates of gastrointestinal adverse events, including ~70% nausea and ~68.6% vomiting, were observed in HARBOR-1, posing a challenge for Kailera's ongoing U.S. trial.
- Significant Weight Loss Efficacy in Obesity Trial: The HARBOR-1 Phase 3 trial, involving adults with obesity or overweight, successfully met its primary endpoint. Patients treated with HRS-7535 achieved a mean weight loss of 8% at 120 mg and 9.8% at 180 mg from baseline by week 44. This compares favorably to a 2.4% reduction in the placebo group, demonstrating a statistically significant and clinically meaningful weight reduction, positioning the drug as a competitive oral option in the obesity landscape.
- Positive Outcomes in Type 2 Diabetes Study: The OUTSTAND-2 Phase 3 trial for type 2 diabetes patients also met its main goal, demonstrating non-inferiority to dapagliflozin (Farxiga). The highest dose of HRS-7535 (90 mg) led to a 1.68% reduction in HbA1c from baseline at 32 weeks, surpassing dapagliflozin's 1.28% reduction. The study also reported improvements in body weight, systolic blood pressure, lipid profiles, and urinary albumin-to-creatinine ratio, indicating broad metabolic benefits.
- Gastrointestinal Safety Profile and Future Optimization: While efficacious, the HARBOR-1 trial reported high rates of gastrointestinal treatment-emergent adverse events (TEAEs), with approximately 70% of patients experiencing nausea and up to 68.6% experiencing vomiting. These rates were higher than in previous studies, leading to analyst concerns. Kailera Therapeutics is actively addressing these safety signals in an ongoing global Phase 2 trial, exploring a wider dose range, lower starting doses, and more gradual titration to optimize the drug's overall clinical profile for diverse patient populations.
Hengrui/Kailera's Oral GLP-1 Achieves Key Endpoints in China
Two pivotal recent trials illustrate the evolving oral GLP-1 landscape in obesity pharmacotherapy. The OASIS-4 trial (2025) evaluated oral semaglutide 25 mg in 307 adults over 64 weeks, demonstrating a mean body weight reduction of 13.6%, with 63% of participants achieving ≥10% weight loss alongside favourable metabolic changes. Gastrointestinal adverse events were consistent with the GLP-1 receptor agonist class, with mild dysesthesia additionally reported. The ATTAIN-1 trial (2025) assessed orforglipron, an oral non-peptide GLP-1 receptor agonist, in 3,127 adults with obesity over 72 weeks. Mean weight loss reached 11.2%, with 54.6% of participants achieving ≥10% reduction and meaningful improvements in cardiometabolic parameters. Safety was similarly characterised by GLP-1-class gastrointestinal effects, with five mild cases of pancreatitis observed.
In the injectable dual agonist space, a 2026 randomised trial of mazdutide 9 mg — a dual glucagon and GLP-1 receptor agonist — in Chinese adults with BMI ≥30 kg/m² without diabetes reported a mean percentage weight change of −12.78% at week 24, versus +1.80% with placebo (treatment difference −14.58%; 95% CI −18.00 to −11.16; p < 0.0001). Weight reduction of ≥5% was achieved by 81.7% of mazdutide-treated participants, accompanied by greater improvements in cardiometabolic risk factors relative to placebo. The most commonly reported adverse events were nausea (50.0% vs. 0% placebo), diarrhoea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity — a tolerability profile consistent with the mechanistic class.
A 2025 Cochrane systematic review of tirzepatide — the approved dual GIP/GLP-1 receptor agonist administered once weekly at doses of 5 mg to 15 mg — synthesised evidence from 8 studies (6,317 participants) at medium-term follow-up (12–18 months), reporting a mean percentage weight reduction of −16.03% (95% CI −18.91 to −13.14; moderate-certainty evidence) and a risk ratio of 3.60 (95% CI 2.44 to 5.30) for achieving ≥5% weight loss. At long-term follow-up (3.5 years; 1 study, 1,032 participants), mean weight reduction was −15.66% (95% CI −19.14 to −12.18). From a safety perspective, non-serious adverse events were elevated at medium term (RR 1.33; 95% CI 1.03 to 1.71; low-certainty evidence), while effects on serious adverse events remained uncertain (RR 0.99; very low-certainty evidence). MACE and mortality showed little to no difference versus comparator at both timepoints, though evidence certainty was moderate to low.
Navigating the Safety Profile of HRS-7535: GI Events in Focus
Across both its Phase 1 (healthy participants) and Phase 2 (type 2 diabetes inadequately controlled with metformin) trials, HRS-7535 has demonstrated a safety and tolerability profile broadly consistent with the established GLP-1 receptor agonist (GLP-1 RA) class. The high completion rate in the Phase 2 trial — 177 of 194 randomized patients (91.2%) completing 16 weeks of treatment — further underscores its overall tolerability.
Gastrointestinal adverse events predominate across both studies: In the Phase 1 trial (SAD, food effect, and MAD parts), nausea and vomiting were the most frequently reported adverse events (AEs). In the Phase 2 trial, AEs occurred in 71.8%–84.6% of HRS-7535-treated patients versus 71.8% of placebo-treated patients, with events characterized as predominantly mild to moderate in severity and gastrointestinal in nature.
Hypoglycemia risk appears low and confined to Grade 1 events: In the Phase 2 trial, Level 1 hypoglycemia was recorded in 9 HRS-7535-treated patients; no Level 2 or Level 3 hypoglycemic events were observed, suggesting a limited risk of clinically significant hypoglycemia in a metformin-combination setting.
No pancreatic or hepatic safety signals were identified: The Phase 2 trial recorded no cases of pancreatitis and no elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 3× the upper limit of normal, indicating an absence of concerning pancreatic or hepatotoxic findings to date.
Phase 1 pharmacokinetics support a once-daily oral regimen: Beyond tolerability, the Phase 1 trial confirmed that HRS-7535's pharmacokinetic profile is suitable for once-daily dosing, with the MAD cohort receiving HRS-7535 120 mg (via a 30/60/90/120 mg titration scheme) over 28 days without emergent safety concerns.
HRS-7535 in the Oral GLP-1 Landscape: US Market Challenges
The investigational pharmacotherapy landscape for obesity has undergone a marked transformation, with GLP-1 receptor agonists, dual and triple incretin agonists, and amylin-based combination therapies demonstrating unprecedented efficacy in clinical trials. Recent data indicate that some agents induce 15–25% body weight reduction, approaching outcomes historically exclusive to surgical intervention. Oral semaglutide 25 mg, approved for obesity treatment based on the OASIS programme, is particularly notable: in patients with overweight/obesity without type 2 diabetes (T2D), it achieved weight reductions of 16.3% and 14.7% for the trial product and treatment policy estimands, respectively. In those with concomitant T2D, reductions of 9.4% and 7.8% were observed. Critically, 82.2% of participants treated with oral semaglutide 25 mg achieved systemic exposure levels within the same range as those receiving once-weekly subcutaneous semaglutide 2.4 mg in STEP 1, with overall efficacy profiles considered comparable between the two formulations. Earlier-generation anti-obesity medications — including phentermine/topiramate, liraglutide, naltrexone/bupropion, and orlistat — achieved more modest placebo-subtracted weight reductions ranging from 2.9% to 6.8% across meta-analyses of ≥12-month trials, underscoring the step-change in efficacy represented by newer incretin-based agents.
Against this evolving pharmacotherapy benchmark, bariatric surgery has historically been considered the most effective intervention for severe obesity. Cost-effectiveness analyses with long time horizons for patients with BMI >35 kg/m² found that four of fifteen adapted studies classified bariatric surgery as cost-saving (dominant) versus conventional treatment, with the remainder demonstrating ICERs below CHF 50,000 per QALY gained. For patients with BMI <35 kg/m², two studies similarly returned ICERs below 50,000 per QALY, and gastric bypass demonstrated superiority over gastric banding, albeit at higher cost. However, the emergence of pharmacotherapies achieving 15–25% weight loss now challenges the established criteria for surgical candidacy, and a stepwise pharmacotherapy-first approach may be justified, particularly in patients with BMI in the 30–40 kg/m² range. A large retrospective analysis of 261,408 adults with BMI ≥35 further highlighted that clinical obesity — defined by the presence of at least one obesity-related condition — was associated with significantly higher odds of post-treatment complications within 90 days compared to pre-clinical obesity, for both anti-obesity medications (aOR 1.10, p<0.001) and bariatric surgery (aOR 1.39, p<0.001), reinforcing the importance of patient stratification in treatment selection.
Non-pharmacological and device-based interventions occupy a distinct niche, generally demonstrating more modest and anatomically localised effects. Among non-invasive modalities, radiofrequency produced a pooled mean abdominal circumference reduction of 2.7 cm (95% CI: 2.3–3.1), while lipolysis achieved a pooled reduction in fat layer thickness of 78% (95% CI: 73–83%), and liposuction yielded a pooled weight loss of 3.01 kg (95% CI: 2.3–3.6). Notably, cost analyses revealed no significant differences between non-invasive and invasive interventions, with non-invasive approaches appearing to offer superior clinical efficacy in body shape metrics at comparable or lower cost. Behavioural interventions such as alternate-day fasting and 16/8 time-restricted fasting demonstrated statistically significant reductions in body weight, BMI, waist circumference, blood glucose, and triglycerides versus control in overweight/obese adults with prediabetes, with alternate-day fasting producing greater reductions in body weight and BMI than the 16/8 protocol. Taken together, the published evidence positions next-generation oral and injectable incretin-based therapies as the most clinically transformative investigational and recently approved options relative to established standards of care, with non-pharmacological approaches retaining utility in defined patient subgroups.
Frequently Asked Questions
References
- [1] De Oliveira-Gomes D, de Majo AM et al.. Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions. Current atherosclerosis reports. 2026 Feb 13. 41686329
- [2] Jones JA, Fayad LE et al.. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leukemia & lymphoma. 2010 Sep. 20807093
- [3] Chen LL, Tohit NM et al.. Predictors of suboptimal glycemic control in people with type 2 diabetes and overweight or obesity: insights from baseline analysis of a diabetes-specific meal replacement study. Frontiers in nutrition. 2025. 41601869
- [4] Vermeiren E, Naets T et al.. Improving Treatment Outcome in Children With Obesity by an Online Self-Control Training: A Randomized Controlled Trial. Frontiers in pediatrics. 2021. 35004547
- [5] Alexander L, Purnell JQ et al.. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach. Obesity (Silver Spring, Md.). 2026 Apr. 41782434
- [6] Ostrominski JW, Chhibber A et al.. Obesity Medication Treatment Perspectives Among People with Overweight or Obesity. Patient preference and adherence. 2025. 40969562
- [7] Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabolism open. 2026 Jun. 41948476
- [8] Chianelli M, Busetto L et al.. From awareness to action: evolving endocrinologist practices in obesity treatment in Italy. Frontiers in endocrinology. 2025. 41244051
- [9] Pennington B, Cummins E et al.. Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity. PharmacoEconomics. 2025 Oct. 40717166
- [10] Aldahi WA, Alenezi A et al.. Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2026 Mar. 41678007
- [11] Mastorino L, Dapavo P et al.. Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years. Clinical and experimental dermatology. 2025 Dec 23. 40700470
- [12] Ademi Z, Tomonaga Y et al.. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss medical weekly. 2018. 29894556
- [13] Masood M, Sharaiha RZ et al.. Endobariatric Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. Biomedicines. 2026 Feb 2. 41751244
- [14] Najjar RH, Alrashid SO et al.. Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: A Clinical Experience. Saudi medical journal. 2026 Jul. 42293717
- [15] Rojas L, Muñiz S et al.. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. PloS one. 2020. 32023267
- [16] Kelly AS, Metzig AM et al.. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring, Md.). 2012 Feb. 22076596
- [17] Overgaard RV, Birkhan O et al.. Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. Diabetes, obesity & metabolism. 2026 Jul. 42023428
- [18] Rubio-Herrera MA, Mera-Carreiro S. Weight management treatment in obesity. Medicina clinica. 2025 Nov. 40865172
- [19] Philis-Tsimikas A, Wysham CH et al.. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. Journal of diabetes and its complications. 2019 Mar. 30600137
- [20] Sofen HL, Gogineni R et al.. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatology and therapy. 2026 Jun. 42105056
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com














